SecBot SecBot

RXST

RxSight, Inc.
Nasdaq· Ophthalmic Goods· Inc. DE· CIK 0001111485 Healthcare & Medical Devices
$5.02 −0.06 (−1.18%)
Oct 23 4:00 PM ET · prev $5.08
Market cap
$211.3M
Micro cap
Consensus
Hold
7% Buy or better · 15 analysts
Median target
$6.65
+32% · range $5.50–11.00
Next earnings
Nov 3
in 8 days · EPS est. −$0.19
1 year
−42.0%
from $8.66 · Oct 27
30 days
+7.5%
from $4.67
52-week range
$4.51–13.09
−62% from high · low Oct 16
Avg volume 20D
678.8K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$118.0K
0 buyers · 4 sellers · since Jun 17
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
4
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 3, 2026
Strongest BEARISH Four RxSight insiders, including the CFO, CMO, and COO, sold a total of $118K in open-market shares on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S Sep 2 4 insiders sell $118.0K at $6.96

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $118.0K.

  • InstitutionsBULLISH

    Q2 2026: 28 added (0 new), 17 trimmed or exited.

  • AnalystsMIXED

    1 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.168 → −$0.188 over 90 days. 1 up, 3 down in 30 days.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
BlackRock, Inc.ADD5,790,408$27.9M
MILLENNIUM MANAGEMENT LLCADD3,030,287$14.6M
UBS Group AGDOUBLED1,016,066$4.9M
MARSHALL WACE, LLPDOUBLED995,916$4.8M
Schonfeld Strategic Advisors LLCDOUBLED701,417$3.4M
CITADEL ADVISORS LLCTRIM700,736$3.4M
Trexquant Investment LPDOUBLED607,935$2.9M
DEUTSCHE BANK AG\TRIM540,208$2.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Hold 7% rate it Buy or better
Strong Buy0Buy1Hold9Sell3Strong Sell2
12-month targets · 8 analysts

Price is below the lowest target. Median implies +32%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 22, 2026Jefferies
MAINTAIN
MAINTAINHold
Sep 22, 2026B of A Securities
MAINTAIN
MAINTAINUnderperform
Aug 10, 2026Stifel
MAINTAIN
MAINTAINHold
Aug 6, 2026UBS
MAINTAIN
MAINTAINNeutral
Jul 7, 2026B of A Securities
MAINTAIN
MAINTAINUnderperform
Jul 7, 2026Needham
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$118.0K
sold · 4 insiders
DateInsiderTypeValue
Sep 15, 2026
Weinberg Eric
See remarks
EXERCISE$152.6K
Sep 5, 2026
Wilterding Mark
Chief Financial Officer
TO ISSUER258,770 sh
Sep 5, 2026
Wilterding Mark
Chief Financial Officer
AWARD258,770 sh
Sep 5, 2026
Weinberg Eric
See remarks
TO ISSUER87,437 sh
Sep 5, 2026
Weinberg Eric
See remarks
TO ISSUER95,000 sh
Sep 5, 2026
Weinberg Eric
See remarks
AWARD65,742 sh
Sep 5, 2026
Kurtz Ronald M MD
Chief Medical Officer
TO ISSUER338,819 sh
Sep 5, 2026
Weinberg Eric
See remarks
TO ISSUER92,200 sh

Earnings setup

Estimates
Nov 3
reports in 8 days
−$0.19
EPS estimate, this quarter
−12%
estimate change, 90 days
1↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.31–$0.09-22.8%$27.2M
Next Q🔒 Fresh data, subscribers only
Current FY-$0.28-$0.47–-$0.16-1.0%$147.1M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 24, 2026 Other
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced
Oct 20, 2026 Press
RxSight announced it will report Q3 2026 financial results on an unspecified date. The press release contains no…
Impact 2/10
Sep 15, 2026 Insider
Weinberg Eric acquired via exercise 35,168 shares
See remarks @ $4.34 ($152.6K)
Sep 5, 2026 Insider
Wilterding Mark disposed of 258,770 shares
Chief Financial Officer
Sep 5, 2026 Insider
Wilterding Mark was granted 258,770 shares
Chief Financial Officer
Sep 2, 2026 SEC
Four RxSight insiders, including the CFO, CMO, and COO, sold a total of $118K in open-market shares on September 2…
CLUSTER — Impact 4/10
Sep 2, 2026 SEC
Three C-suite insiders at RxSight (CFO, CMO, COO) sold a total of $104K in open-market sales on September 2, 2026…
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
5,790,408 shares ($27.9M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
RXST Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Oct 24, 2026
Press release
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted…
Oct 20, 2026
Activist
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for…
Aug 26, 2026
Company news
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in…
Aug 5, 2026
Earnings date
RXST Q2 2026 Earnings Scheduled — 2026-08-05
Jul 26, 2026
Press release
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted…

SecBot reports

4 filings · 1 press release · 0 bullish · 1 bearish · 3 neutral
All RXST filing & press-release reports (5)